Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 64Neoplasms 38Venous Thromboembolism 29Leukemia 21Anemia, Refractory, with Excess of Blasts 20Myelodysplastic Syndromes 19Lymphoma 14Thrombocytopenia 13Multiple Myeloma 12Leukemia, Myelomonocytic, Chronic 12Venous Thrombosis 11Pulmonary Embolism 11Febrile Neutropenia 11Breast Neoplasms 10Myeloproliferative Disorders 9Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Neoplasms, Plasma Cell 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Primary Myelofibrosis 6Neutropenia 6Hodgkin Disease 6Hemophilia A 6Lung Neoplasms 5Anemia, Refractory 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precancerous Conditions 4Lymphoproliferative Disorders 4

Interventions

maltodextrin 1Glutamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Vaso-Occlusive Crises × Classical hematology × Clear all
NCT01179217 2020-08-19

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Emmaus Medical, Inc.

Phase 3 Completed
230 enrolled 19 charts 1 FDA
Classical hematology

Vaso-Occlusive Crises, Anemia, Sickle Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡